JP2013166753A5 - - Google Patents

Download PDF

Info

Publication number
JP2013166753A5
JP2013166753A5 JP2013029277A JP2013029277A JP2013166753A5 JP 2013166753 A5 JP2013166753 A5 JP 2013166753A5 JP 2013029277 A JP2013029277 A JP 2013029277A JP 2013029277 A JP2013029277 A JP 2013029277A JP 2013166753 A5 JP2013166753 A5 JP 2013166753A5
Authority
JP
Japan
Prior art keywords
medicament
daily dose
formulating
methyl
ethinyl estradiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013029277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013166753A (ja
JP5883810B2 (ja
Filing date
Publication date
Priority claimed from DE102005023301A external-priority patent/DE102005023301B4/de
Priority claimed from DE102006016285A external-priority patent/DE102006016285A1/de
Application filed filed Critical
Publication of JP2013166753A publication Critical patent/JP2013166753A/ja
Publication of JP2013166753A5 publication Critical patent/JP2013166753A5/ja
Application granted granted Critical
Publication of JP5883810B2 publication Critical patent/JP5883810B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013029277A 2005-05-13 2013-02-18 プロゲストゲン及び/又はエストロゲン及び5−メチル−(6s)−テトラヒドロフォレートを含んで成る医薬組成物 Active JP5883810B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102005023301.5 2005-05-13
DE102005023301A DE102005023301B4 (de) 2005-05-13 2005-05-13 Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
DE102006016285.4 2006-04-03
DE102006016285A DE102006016285A1 (de) 2006-04-03 2006-04-03 Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008510518A Division JP2008540482A (ja) 2005-05-13 2006-05-15 プロゲストゲン及び/又はエストロゲン及び5−メチル−(6s)−テトラヒドロフォレートを含んで成る医薬組成物

Publications (3)

Publication Number Publication Date
JP2013166753A JP2013166753A (ja) 2013-08-29
JP2013166753A5 true JP2013166753A5 (OSRAM) 2016-02-12
JP5883810B2 JP5883810B2 (ja) 2016-03-15

Family

ID=37396913

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008510518A Withdrawn JP2008540482A (ja) 2005-05-13 2006-05-15 プロゲストゲン及び/又はエストロゲン及び5−メチル−(6s)−テトラヒドロフォレートを含んで成る医薬組成物
JP2013029277A Active JP5883810B2 (ja) 2005-05-13 2013-02-18 プロゲストゲン及び/又はエストロゲン及び5−メチル−(6s)−テトラヒドロフォレートを含んで成る医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008510518A Withdrawn JP2008540482A (ja) 2005-05-13 2006-05-15 プロゲストゲン及び/又はエストロゲン及び5−メチル−(6s)−テトラヒドロフォレートを含んで成る医薬組成物

Country Status (37)

Country Link
US (2) US20080160004A1 (OSRAM)
EP (3) EP2116249B2 (OSRAM)
JP (2) JP2008540482A (OSRAM)
KR (2) KR20080028369A (OSRAM)
CN (2) CN101954083A (OSRAM)
AR (1) AR054123A1 (OSRAM)
AT (2) ATE555791T1 (OSRAM)
AU (1) AU2006245921A1 (OSRAM)
BR (1) BRPI0611443B8 (OSRAM)
CA (1) CA2608639C (OSRAM)
CL (2) CL2009002187A1 (OSRAM)
CR (1) CR9531A (OSRAM)
CY (2) CY1109261T1 (OSRAM)
DE (1) DE502006003617D1 (OSRAM)
DK (2) DK2116249T3 (OSRAM)
DO (1) DOP2006000110A (OSRAM)
EA (2) EA014664B1 (OSRAM)
EC (1) ECSP078001A (OSRAM)
ES (2) ES2325600T3 (OSRAM)
GT (1) GT200600200A (OSRAM)
HR (1) HRP20090418T1 (OSRAM)
IL (1) IL187340A (OSRAM)
MA (1) MA29448B1 (OSRAM)
MY (1) MY147362A (OSRAM)
NO (1) NO345807B1 (OSRAM)
PE (1) PE20061415A1 (OSRAM)
PL (2) PL2116249T3 (OSRAM)
PT (2) PT2116249E (OSRAM)
RS (2) RS50972B (OSRAM)
SG (1) SG169973A1 (OSRAM)
SI (2) SI2116249T1 (OSRAM)
SV (1) SV2008002527A (OSRAM)
TN (1) TNSN07418A1 (OSRAM)
TW (1) TWI380820B (OSRAM)
UY (1) UY29527A1 (OSRAM)
WO (1) WO2006120035A2 (OSRAM)
ZA (2) ZA200710811B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
CA2665788A1 (en) * 2006-07-06 2008-01-10 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical preparations for contraception and for preventing the risk of congenital malformations
EP1891959A1 (de) * 2006-08-14 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
MX2009010763A (es) * 2007-04-05 2009-10-28 Bayer Schering Pharma Ag NUEVO REGIMEN DE DROSPIRENONA/17ß-ESTRADIOL, PRODUCTO FARMACEUTICO COMBINADO Y CONJUNTO DE ELEMENTOS (KIT) PARA SU APLICACION.
EA201070715A1 (ru) * 2007-12-20 2011-02-28 Тева Вимен'С Хелс, Инк. Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции
TW200946542A (en) * 2008-03-10 2009-11-16 Vladimir Hanes New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
TW200942242A (en) * 2008-03-10 2009-10-16 Rolf Schurmann New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
MX356702B (es) 2010-04-15 2018-06-11 Bayer Ip Gmbh Formas de dosificación sólidas orales con dosis muy bajas para la hrt.
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP2617422A1 (en) * 2012-01-20 2013-07-24 Isofol Medical AB Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate
EP2781214A1 (en) 2013-03-22 2014-09-24 Chemo Research, S.L. Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
CN104490887A (zh) * 2014-09-04 2015-04-08 连云港金康和信药业有限公司 (6s)-5-甲基-四氢叶酸钙盐的稳定药物组合物
MY195019A (en) 2015-06-18 2023-01-03 Estetra Sprl Orodispersible dosage unit containing an estetrol component
JP6866560B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
HUE054589T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Szájban diszpergálódó esztetrol tartalmú tabletta
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
CN106336444A (zh) * 2016-08-23 2017-01-18 国家卫生计生委科学技术研究所 一种新晶型炔雌醇
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK174724B1 (da) * 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
ZA939565B (en) * 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for preparing low dose pharmaceutical products.
US6083528A (en) * 1995-09-28 2000-07-04 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
AU7522896A (en) * 1995-10-27 1997-05-15 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
CN1122456C (zh) 1996-01-31 2003-10-01 南亚拉巴马医学科学基金会 含有天然的还原叶酸盐异构体的食品和维生素制品
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
UA68365C2 (en) * 1997-11-06 2004-08-16 Wyeth Corp Peroral contraception by combination of anti-estrogen and progestin
CN1240387C (zh) * 1998-04-17 2006-02-08 奥索一麦克尼尔药品公司 含有叶酸的药用组合物及其用途和给药系统
US7014865B1 (en) 1998-10-19 2006-03-21 Merck Patent Gmbh Natural formulation for the treatment and prevention of depression, containing St. John's Wort and derivatives of dihydro- and tetrahydrofolic acid
CA2348693C (en) * 1998-10-19 2008-07-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Natural formulation for the treatment and prevention of depression, containing st john's wort and derivatives of dihydro- and tetrahydrofolic acid
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
HU225779B1 (en) 1999-07-28 2007-08-28 Chinoin Gyogyszer Es Vegyeszet Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
ES2319750T3 (es) 1999-08-31 2009-05-12 Bayer Schering Pharma Aktiengesellschaft Composicion farmaceutica que comprende etinilestradiol y drospirenona para usar como anticonceptivo.
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US6479545B1 (en) 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
DE10022510A1 (de) 2000-05-10 2001-11-15 Basf Ag Zusammensetzungen enthaltend Folsäure und reduziertes Folat
CA2433949A1 (en) * 2000-12-14 2002-10-24 Tufts University Compositions and methods for treating an arthritic condition
US20030045510A1 (en) * 2000-12-15 2003-03-06 Schloss Caroline Maxine Estrogen-plus
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
US20040220118A1 (en) * 2001-02-02 2004-11-04 Bland Jeffrey S. Medical composition for balancing bodily processes
US20060034954A1 (en) * 2001-02-02 2006-02-16 Bland Jeffrey S Medical composition for balancing bodily processes
CA2476940C (en) * 2002-02-21 2011-11-01 Herman Jan Tijmen Coelingh Bennink Pharmaceutical compositions comprising one or more steroids, one or more tetrahydrofolate components and vitamin b12
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.

Similar Documents

Publication Publication Date Title
JP2013166753A5 (OSRAM)
CA2608639A1 (en) Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate
JP2848919B2 (ja) 前更年期のホルモン異常の治療用、更年期のホルモン補充療法用、アンドロゲン誘引性障害の治療用および避妊用医薬
JP2008540482A5 (OSRAM)
JP2010508275A5 (OSRAM)
AU2021262853B2 (en) Contraceptive compositions and methods for improved efficacy and modulation of side effects
JP2008505909A5 (OSRAM)
US12390476B2 (en) Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen
RU2009120528A (ru) Способы гормональной терапии возрастающими дозами в режиме пролонгированного цикла
JP5810159B2 (ja) ドロスピレノンを含む医薬組成物及び避妊用キット
JP2019163318A5 (OSRAM)
JP2007535519A5 (OSRAM)
JP2009542591A5 (OSRAM)
PE20080273A1 (es) Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico
CA2267743A1 (en) Low dose estrogen interrupted hormone replacement therapy
CA2422974A1 (en) Medicaments based on progestins for dermal use
CN101267827A (zh) 口服曲美孕酮避孕
US8119620B2 (en) Dosage form for hormonal contraception
JP2008515909A5 (OSRAM)
WO2002094281A1 (en) Means and method for hormonal contraception
EP2263659A1 (de) Folsäurehaltiges Kontrazeptivum
JP2003535127A (ja) 低用量経口避妊薬用のスターターキット
US20060089338A1 (en) Dosage form for hormonal contraception
JP2014508809A5 (OSRAM)
US20080280861A1 (en) Method of Female Contraception and a Kit For Use Therein